264 Rat and Human Bladder Urothelial Cells Have Decreased Atp-Evoked Increase in Intracellular Calcium With Knockdown of P2y2 Receptor

Sterling, Kathleen; Roth, Joshua A.; Laaris, Nora; Chai, Toby C.; Sun, Yue

doi:10.1016/j.juro.2012.02.321

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In healthy cats, P2X1-7 and P2Y 1,2,4 receptor subtypes were expressed throughout the bladder epithelium [63] and P2Y 2 , and to a lesser extent P2Y 4 , receptors in the urothelium of rats [153]. Knockdown of P2Y 2 receptor expression using small interfering RNA resulted in reduction of ATP-evoked rise in [Ca 2+ ] i in both human and rat bladder urothelial cells [636]. It has been reported recently that uridine diphosphate (UDP), via P2Y 6 receptors, increases voiding frequency in humans via release of ATP from the urothelium and autocrine reinforcement of its release [616].…”

Section: Ectoenzymatic Breakdown Of Atpmentioning

confidence: 99%

Purinergic signalling in the urinary tract in health and disease

Burnstock

2013

Purinergic Signalling

140

149

View full text Add to dashboard Cite

Purinergic signalling is involved in a number of physiological and pathophysiological activities in the lower urinary tract. In the bladder of laboratory animals there is parasympathetic excitatory cotransmission with the purinergic and cholinergic components being approximately equal, acting via P2X1 and muscarinic receptors, respectively. Purinergic mechanosensory transduction occurs where ATP, released from urothelial cells during distension of bladder and ureter, acts on P2X3 and P2X2/3 receptors on suburothelial sensory nerves to initiate the voiding reflex, via low threshold fibres, and nociception, via high threshold fibres. In human bladder t h e p u r i n e rg i c c o m p o n e n t o f p a r a s y m p a t h e t i c cotransmission is less than 3 %, but in pathological conditions, such as interstitial cystitis, obstructed and neuropathic bladder, the purinergic component is increased to 40 %. Other pathological conditions of the bladder have been shown to involve purinoceptor-mediated activities, including multiple sclerosis, ischaemia, diabetes, cancer and bacterial infections. In the ureter, P2X7 receptors have been implicated in inflammation and fibrosis. Purinergic therapeutic strategies are being explored that hopefully will be developed and bring benefit and relief to many patients with urinary tract disorders.

show abstract

Section: Ectoenzymatic Breakdown Of Atpmentioning

confidence: 99%